london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Effect of triamcinolone intravitreal injection in previously vitrectomized eyes

Poster Details

First Author: N.Gomes PORTUGAL

Co Author(s):    K. Sousa   L. Mendonça   R. Gentil   G. Calvão-Santos   R. Leite   J. Mendes   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To analyze the duration of effect of triamcinolone acetonide intravitreal injection (TA IVI) on central macular thickness in previously vitrectomized eyes.

Setting:

Ophthalmology department of Hospital de Braga, Portugal.

Methods:

Retrospective study including previously vitrectomized eyes with persistent macular edema. Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), indirect fundoscopy and Central Macular Thickness changes were observed in all patients previously and after TA IVI. Optical Coherence Tomography (OCT) - Cirrus TM HD-OCT Zeiss Meditec® - was used for central macular thickness measurement.

Results:

22 pseudophakic eyes of 18 patients were included with a mean (± standard deviation SD) age of 68.2±8.65 years. Macular edema was related to diabetic retinopathy (n=20 eyes), and followed vitrectomy for retinal detachment (n=1) and ocular trauma (n= 1). Mean (±SD) interval between pars plana vitrectomy and TA IVI was 11.12±4.5 months. Mean (±SD) intraocular pressure increased significantly from 16.45±2.58 mmHg at baseline to 19.85±3.34 mmHg after TA IVI (p=0.0041, paired sample t-test). Mean baseline Central Macular Thickness (±SD) was 489±145 μm. First measurement was 17.91±10.2 days post-TA IVI and the mean Central Macular Thickness (±SD) was 229±171 μm (p=0.0012 vs. baseline; paired sample t-test). Second measurement was 81.36±24.25 days post-TA IVI and mean (±SD) Central Macular Thickness was 355±121 μm (p=0.0315 vs. baseline; paired samples t-test). Central Macular Thickness-lowering effect of triamcinolone in vitrectomized eyes lasted a mean (±SD) of 11.62±3.46 weeks.

Conclusions:

Triamcinolone should be considered in the treatment of patients with persistent macular edema non-responsive to other standard-of-care therapies. Central Macular Thickness-lowering effect of triamcinolone in vitrectomized eyes approached the time-range of 12 to 14 weeks set for non-vitrectomized eyes.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy